SoftOx småprat

[chris3]

dagens ledelse er av topp kvalitet, og de fremstår veldig troverdige…

[TekBot]

SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Reference is made to the stock notice from SoftOx Solutions AS (the “Company”) on 14 August 2025 regarding the financing facility with Long State Investments Limited.
…

Vis børsmeldingen

Softox Solutions AS (“SoftOx”) today announces that the board of directors has resolved a private placement at a subscription price of NOK 0.0725, with Long State subscribing for 45 000 000 shares in the Company. The subscription price corresponds to the procedure outlined in the Equity Placement Agreement. In accordance with the financing facility, Long State received a placement commission on market terms.

Following the private placements, the new share capital of the Company will be NOK 48 708 339.88 divided into 2 435 416 994 shares, each with a par value of NOK 0.02.

For more information on the financing facility, please see the Company’s stock exchange release dated 14 August 2025.

Deviation from shareholders’ preferential rights
The board of directors has considered the private placement in light of the equal treatment principles under the Norwegian Securities Trading Act and Oslo Børs’ Oslo Rule Book II – Membership and Trading Rules and Oslo Børs’ Circular no. 2/2014, and is of the opinion that the waiver of the preferential rights inherent in the following private placement is considered necessary in the interest of time and successful completion in order to secure funding of SoftOx. Taking into consideration the time, costs, and expected terms of alternative methods of securing the necessary funding, the board of directors concluded that the completion of the private placements, including the waiver of the preferential rights inherent to the private placements, is in the common interest of the shareholders of SoftOx. Further, the board assessed whether a subsequent offering should be carried out. As the private placement is limited and considering the cost inherent in a subsequent offering, the board concluded that a subsequent offering shall not be carried out.

For further information, please contact:
Ulrik Spork, COB Soft Solutions AS, +45 31 38 83 87
Ingrid Juven, CFO SoftOx Solutions AS, +47 918 76 165

Mail: ir@soft-ox.com
About SoftOx Solutions AS: SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo. The company is developing highly effective pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. The technology is based on extensive research and development in partnership with leading Nordic research institutes.

Kilde

[TekBot]

SoftOx Solutions AS: New Share Capital

Reference is made to the stock exchange release from SoftOx Solutions AS (the “Company”) on 23 January 2026 regarding the board resolution to increase the share capital by carrying out a private placement of NOK 3 262 500 under the financing facility with the investment fund Long State Investments Limited (“Long State”).

The new share capital, following completion of the private placement, has today been registered with the Norwegian Register of Business Enterprises.
…

Vis børsmeldingen

The new share capital of the Company is NOK 48 708 339.88 divided into 2 435 416 994 shares, each with a par value of NOK 0.02.

For more information on the financing facility, please see the Company’s stock exchange release dated 14 September 2025.

For further information, please contact:
Ulrik Spork, COB Soft Solutions AS, +45 31 38 83 87
Ingrid Juven, CFO SoftOx Solutions AS, +47 918 76 165
Mail: ir@soft-ox.com

About SoftOx Solutions AS:
SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo. The company is developing highly effective pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. The technology is based on extensive research and development in partnership with leading Nordic research institutes.

Kilde

[TekBot]

SoftOx Defense Solutions AS: HPRA Approves SIS-02 Phase 1 Trial, Strengthening Dual-Use and Preparedness Strategy

Oslo / Dublin: SoftOx Defense Solutions AS (“SoftOx”) announces that the Health Products Regulatory Authority (HPRA) in Ireland has approved the Company’s clinical trial application (CTA) for the SIS-02 Phase 1 clinical study in healthy volunteers.

The SIS-02 study will evaluate the safety, tolerability, and pulmonary exposure profile of SoftOx’s inhalation solution. The approval represents a critical execution milestone, transitioning SIS into controlled human testing and establishing the human safety and dosing foundation required for both civilian development and preparedness-oriented pathways, including defence and biological countermeasure applications.
…

Vis børsmeldingen

Strategic and Scientific Significance
Approval of SIS-02 confirms the readiness of SoftOx’s inhalation platform for human clinical evaluation and validates the Company’s development capabilities across GMP manufacturing, regulatory documentation, and clinical execution.

Conducting SIS-02 enables SoftOx to:
Establish robust human safety and tolerability data
Characterize pulmonary dose and exposure
Generate foundational human data required for emergency-use and preparedness-relevant development routes

Business Implications: Parallel Clinical and Preparedness Execution
With the approval of SIS-02, SoftOx now has two regulatory-approved clinical trials, following the previously announced Phase 2a approval by the Danish Medicines Agency.

This positions the Company to move from sequential development into parallel execution, including:
Phase 1 human safety and exposure (Ireland)
Phase 2a dose escalation and early proof-of-concept in cystic fibrosis (Denmark)

The establishment of human safety and dosing data across these programs also enables SoftOx to consider programs for Dual-use and preparedness-oriented development activities in parallel with clinical execution.

Value and Relevance for Dual-Use and Biodefence Preparedness
SoftOx’s SIS platform is being developed as a broad-spectrum, non-antibiotic inhaled therapeutic with attributes relevant to modern biodefence and medical countermeasure strategies, including:
Activity against bacteria, viruses, and fungi addressing diverse airborne biological threats
Low risk of resistance development, preserving long-term effectiveness and deployment flexibility
Local airway administration enabling rapid onset at the primary site of exposure
Scalable manufacturing and formulation stability are potentially compatible with stockpiling and rapid deployment frameworks

These attributes create potential optionality for future preparedness-oriented development pathways, contingent upon clinical validation and strategic or non-dilutive funding support.

If pursued, this would enable the SIS platform to address both chronic respiratory disease and defence-relevant biological threats within national resilience and pandemic response architectures.

While the dual-use profile thus enhances the long-term commercial flexibility of the platform, it does not alter the current clinical development focus, nor jeopardize the financial discipline applied in execution.

CEO, Thomas Bjarnsholt, comments:
“The approval of SIS-02 by HPRA in Ireland is a key execution milestone for SoftOx. It establishes the human safety and dosing foundation of our inhalation platform and, together with our already approved Phase 2a program, enables us to advance civilian development while progressing preparedness-oriented and defence-relevant applications in parallel.”

Next step
Following approval, SoftOx will proceed with clinical site initiation and dosing of healthy volunteers in accordance with the approved protocol.

For further information, please contact:
Ulrik Spork, Chairman of the Board, SoftOx Solutions AS, +45 31 38 83 87
Thomas Bjarnsholt, CEO, SoftOx Solutions AS, +45 20 65 98 88
Mail: ir@soft-ox.com

About SoftOx Solutions AS
SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo. The Company develops innovative, non-antibiotic antimicrobial inhalation therapies targeting bacteria, viruses, and fungi, with applications spanning civilian healthcare, public health preparedness, and future biological countermeasures.

Kilde

[Mrodseth]

Er det noen som vil bli med i et lukket forum for diskusjon av aksjen?
Er for mye u sakelig pjatt fra folk som bare vil ha aksjen opp eller ned kortsiktig her.

Signal Messenger Group

[rockpus]

Trist om det ikke skulle være mulig å diskutere seriøst på dette forumet?

[TekBot]

SoftOx Solutions AS: First Subject Dosed in Combined Phase 2a Dose-Escalation and Proof-of-Concept Trial (SIS-03)

Oslo / Copenhagen: SoftOx Solutions AS (“SoftOx”) today announces that First Subject First Dosing (FSFD) has been successfully completed in the SIS-03 clinical trial in Denmark. This milestone marks the operational initiation of the previously approved combined Phase 2a dose-escalation and proof-of-concept (PoC) study of SoftOx Inhalation Solution (SIS) and represents a key step toward the Company’s next defined value inflection point.

SIS-03 is the regulatory-approved Phase 2a study approved by the Danish Medicines Agency and structured as a combined clinical program consisting of:
…

Vis børsmeldingen

• A dose-escalation component designed to confirm safety and tolerability at increasing dose levels
• A proof-of-concept (PoC) component in people with cystic fibrosis (CF), assessing safety at higher doses and generating key data on bacterial load reduction in the CF airway environment

With first dosing now achieved, the program has transitioned from regulatory clearance to active clinical execution. Importantly, the study is supplied with a GMP-manufactured drug product produced from the previously announced GMP drug substance, confirming full CMC readiness and removing manufacturing risk from the Phase 2a pathway.

Advancing Toward a Defined Value Inflection Point
The combined study structure enables SoftOx to advance safety confirmation and early patient evaluation within a single integrated framework. The dose-escalation phase acts as a gating step toward the PoC component, ensuring a disciplined and capital-efficient development trajectory.

Data generated from SIS-03 are expected to:
• Confirm tolerability at escalated dose levels
• Provide first patient-based signals on bacterial load reduction in CF

Commercial Relevance
Cystic fibrosis represents a well-established market for chronic inhaled antimicrobial therapy, with approximately 13,000 patients across the US and EU4+UK currently receiving treatment, corresponding to an annual market exceeding USD 600 million.

Beyond CF, the same biofilm-targeting mechanism of SIS is applicable to significantly larger respiratory indications, including non-CF bronchiectasis, affecting approximately 445,000 treatable patients across the US and Europe and representing a multi-billion USD annual market opportunity.

The Phase 2a readout is therefore expected not only to validate the clinical profile of SIS in CF, but also to materially strengthen the strategic and commercial positioning of the platform across broader respiratory indications.

Upcoming Milestones
• 1H 2026: Dose-escalation topline data
• Q1 2027: Final Phase 2a PoC readout

These milestones represent clearly defined catalysts for the Company.

CEO Thomas Bjarnsholt comments:
“First dosing in SIS-03 marks the operational start of our combined Phase 2a program. With regulatory approval secured and GMP manufacturing successfully completed, we are executing according to plan. The upcoming dose-escalation and PoC readouts represent important milestones as we advance SIS toward later-stage development and strategic partnering.”

Following FSFD, SoftOx will continue enrolment and dose escalation in accordance with the approved protocol. Further clinical updates will be communicated to the market as appropriate.

For more information, please contact:
Ulrik Spork, Chairman of the Board, SoftOx Solutions AS, +45 31 38 83 87
Thomas Bjarnsholt, CEO, SoftOx Solutions AS, +45 20 65 98 88
Mail: ir@soft-ox.com

About SoftOx Solutions AS:
SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo. The company is developing highly effective pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. The technology is based on extensive research and development in partnership with leading Nordic research institutes.

Kilde

[rockpus]

@polygon : Hva tenker du om status for dette selskapet nå? De har jo en langt mer seriøs ledelse nå enn før? Hva med den finansielle stilling? SIS representerer jo et ganske stort potensiale?

[TekBot]

SoftOx Solutions AS: SoftOx Solutions AS exercises on the financing facility with Long State Investments Limited

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Reference is made to the stock notice from SoftOx Solutions AS (the “Company”) on 14 August 2025 regarding the financing facility with Long State Investments Limited.
…

Vis børsmeldingen

Softox Solutions AS (“SoftOx”) today announces that the board of directors has resolved a private placement at a subscription price of NOK 0.06, with Long State subscribing for 60 000 000 shares in the Company. The subscription price corresponds to the procedure outlined in the Equity Placement Agreement. In accordance with the financing facility, Long State received a placement commission on market terms.

Following the private placements, the new share capital of the Company will be NOK 49 908 339.88 divided into 2 495 416 994 shares, each with a par value of NOK 0.02.

For more information on the financing facility, please see the Company’s stock exchange release dated 14 August 2025.

Deviation from shareholders’ preferential rights
The board of directors has considered the private placement in light of the equal treatment principles under the Norwegian Securities Trading Act and Oslo Børs’ Oslo Rule Book II – Membership and Trading Rules and Oslo Børs’ Circular no. 2/2014, and is of the opinion that the waiver of the preferential rights inherent in the following private placement is considered necessary in the interest of time and successful completion in order to secure funding of SoftOx. Taking into consideration the time, costs, and expected terms of alternative methods of securing the necessary funding, the board of directors concluded that the completion of the private placements, including the waiver of the preferential rights inherent to the private placements, is in the common interest of the shareholders of SoftOx. Further, the board assessed whether a subsequent offering should be carried out. As the private placement is limited and considering the cost inherent in a subsequent offering, the board concluded that a subsequent offering shall not be carried out.

For further information, please contact:
Ulrik Spork, COB Soft Solutions AS, +45 31 38 83 87
Ingrid Juven, CFO SoftOx Solutions AS, +47 918 76 165
Mail: ir@soft-ox.com

About SoftOx Solutions AS:
SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo. The company is developing highly effective pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. The technology is based on extensive research and development in partnership with leading Nordic research institutes.

Kilde

[TekBot]

SoftOx Solutions AS: New Share Capital

Reference is made to the stock exchange release from SoftOx Solutions AS (the “Company”) on 11 March 2026 regarding the board resolution to increase the share capital by carrying out a private placement of NOK 3 600 000 under the financing facility with the investment fund Long State Investments Limited (“Long State”).

The new share capital, following completion of the private placement, has today been registered with the Norwegian Register of Business Enterprises.
…

Vis børsmeldingen

The new share capital of the Company is NOK 49 908 339.88 divided into 2 495 416 994 shares, each with a par value of NOK 0.02.

For more information on the financing facility, please see the Company’s stock exchange release dated 14 September 2025.

For further information, please contact:
Ulrik Spork, COB Soft Solutions AS, +45 31 38 83 87
Ingrid Juven, CFO SoftOx Solutions AS, +47 918 76 165
Mail: ir@soft-ox.com

About SoftOx Solutions AS:
SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company listed on Euronext Growth Oslo. The company is developing highly effective pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. The technology is based on extensive research and development in partnership with leading Nordic research institutes.

Kilde

[TekBot]

SoftOx Solutions AS: Fourth Quarter Report 2025

Please find attached the Fourth Quarter Report 2025 for SoftOx Solutions AS.
…

Vis børsmeldingen

Kilde

[Sander57]

Hva skjedde med SoftOx i dag, opp 38 prosent?

[Springer]

Vanskelig å si hva som skjedde. Pump og dump før emisjonen? Evt lekkasje av nyheter??

[Sander57]

Så det er altså en emisjon på gang? Hvilke nyheter skulle det i så fall være?

[Chrysler300C]

Emisjon på gang de har en finansiell investor som de henter penger av i ny og ne så d er ikke noe stress !

0,15 imorgen

[laban9]

De hentet penger 11.Mars.
Samme finansiering som circio gjorde.
Det beste hadde sikkert vært å gjort en ganske stor emisjon på 0,1 ish og fått inn penger for en stund.

De har mye spennende på gang👌

[Sander57]

@laban9

De har mye spennende på gang

Som for eksempel?

[Jonnybravo]

@laban9

Det beste hadde sikkert vært å gjort en ganske stor emisjon på 0,1 ish og fått inn penger for en stund.

Er stor emisjon på 0,1 realistisk med dagens kurs på 0,11?

[BidTrader]

Noen som har valgt å investere her i det siste? Virker som kursen har begynt å bevege seg smått oppover.

[Sander57]

Nei, ikke foreløpig. Har en gammel post fra tidligere som snart nærmer seg likevekt, men veldig usikker selv om den har hatt god fart den siste stunden. Det er jo en veldig volatil aksje, men samtdig gjelder det jo å være der dersom det smeller.